Vercise™ DBS Dystonia Prospective Study
ConditionDystonia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age7+
SponsorBoston Scientific Corporation
To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia.
IC1. Meets criteria established in the locally applicable Vercise System Directions for Use (DFU) for dystonia.
IC2. At least 7 years old. Parent or guardian consent is required in patients who are younger than 18 years at the time of consent.
EC1. Meets any contraindication in the Vercise System locally applicable Directions for Use.